Back to Type 2 Diabetes
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT02211261

NCT02211261
Completed Phase 1

Who may be able to join

Who might be able to join this trial:

  • Men and women with Type 2 Diabetes who are not able to become pregnant
  • People who have been taking a stable dose of the diabetes medication metformin (at least 1500mg per day for one part of the study, or at least 1000mg per day for another part) for at least 30 days before the screening appointment
  • People whose blood sugar control, measured by a test called HbA1c, falls within a certain range at screening — between 7–10% for one part of the study, or 6.5–10% for another part
  • People whose blood test shows a certain level of a substance called C-peptide, which indicates the body is still producing some insulin (confirm with trial site for exact values that apply to you)

Who may not be able to join:

  • People who have been diagnosed with Type 1 Diabetes
  • People who have diabetes-related complications that have caused serious damage to major organs
  • People who have a history of long-term inflammation of the pancreas, or who are considered at high risk of developing it
  • People whose high blood pressure is not well managed or controlled
  • People who have previously had a heart attack, stroke, or any related heart or brain procedure

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 1
Sponsor
Pfizer
Registry
clinicaltrials_gov
Start date
15 September 2014
Est. completion
27 January 2017

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants With All-Causality and Treatment Related Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events; Number of Participants With Dose Limiting or Intolerable Adverse Events; Number of Participants With Positive Anti-drug Antibody (ADA) Result

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov